Steven N. Chatfield
Directeur/Membre du Conseil chez Cell Therapy Catapult Ltd.
Profil
Steven N.
Chatfield is currently a Non-Executive Director at Cell Therapy Catapult Ltd.
and a Director at Prokarium Ltd.
and Prokarium Holdings Ltd.
He is also a Non-Executive Director at Vaccitech (UK) Ltd.
Previously, Dr. Chatfield held positions as the Chief Scientific Officer & Development Director at Microscience Ltd.
from 1999 to 2004.
He was also a Director at Wellcome Foundation Ltd.
and served as the Director at the Health Protection Agency in 2009.
Additionally, he was the President of Bio Defense Corp in 2010 and the Executive VP-Strategic Investment Division at Emergent BioSolutions, Inc. from 2013 to 2014.
He also served as the President & Chief Scientific Officer at Emergent Product Development UK Ltd.
from 2005 to 2007.
Dr. Chatfield obtained a doctorate degree from the University of Birmingham.
Postes actifs de Steven N. Chatfield
| Sociétés | Poste | Début |
|---|---|---|
Cell Therapy Catapult Ltd.
 Cell Therapy Catapult Ltd. BiotechnologyHealth Technology Cell Therapy Catapult Ltd. engages in the development, delivery, and commercializing of cell and gene therapy. The company was founded in 2012 and is headquartered in London, the United Kingdom. | Directeur/Membre du Conseil | 07/03/2016 |
Prokarium Ltd.
 Prokarium Ltd. Miscellaneous Commercial ServicesCommercial Services Prokarium Ltd. operates as a biopharmaceutical company that focuses on developing vaccination solutions based on synthetic biology. Its oral vaccine delivery platform Vaxonella stimulates broad protective immune responses applicable to a wide range of diseases. The company is headquartered in Keele, the United Kingdom. | Directeur/Membre du Conseil | 05/10/2021 |
Vaccitech (UK) Ltd.
 Vaccitech (UK) Ltd. Miscellaneous Commercial ServicesCommercial Services Vaccitech (UK) Ltd. researches in and develops seasonal flu vaccines. It engages in clinical programs for universal influenza and prostate cancer, MERS, and preclinical programs for other therapeutic infectious diseases indications. The company was founded by Adrian Hill and Sarah Gilbert and is headquartered in Oxford, the United Kingdom. | Directeur/Membre du Conseil | - |
Prokarium Holdings Ltd.
 Prokarium Holdings Ltd. Miscellaneous Commercial ServicesCommercial Services Prokarium Holdings Ltd. provides management services. The private company is based in London, UK. The British company was founded in 2014. Kristen Albright has been the CEO of the company since 2018. | Directeur/Membre du Conseil | 05/10/2021 |
Anciens postes connus de Steven N. Chatfield
| Sociétés | Poste | Fin |
|---|---|---|
| EMERGENT BIOSOLUTIONS INC. | Corporate Officer/Principal | 31/03/2014 |
Bio Defense Corp
 Bio Defense Corp Chemicals: SpecialtyProcess Industries Part of Investco, Inc., Bio Defense Corp develops bio-chemical defense products used as disinfectants for mail ordered food products. The company is based in Burlington, MA. | President | 01/03/2010 |
| Health Protection Agency | Directeur/Membre du Conseil | 01/01/2009 |
Emergent Product Development UK Ltd.
 Emergent Product Development UK Ltd. Pharmaceuticals: MajorHealth Technology Emergent Product Development (UK) Ltd. develops oral vaccines for typhoid, traveler's diarrhea, hepatitis B, and anthrax. It also develops vaccines for meningitis and another for streptococcal infections for infants. The company is a biotechnology company focused on harnessing the immune system to treat and prevent disease in areas of significant unmet clinical needs. It was founded in 1996 and is located in Wokingham, UK. | President | 31/08/2007 |
Microscience Ltd.
 Microscience Ltd. Pharmaceuticals: MajorHealth Technology Microscience is an emerging vaccine company which is primarily involved in the discovery and development of innovative, rationally designed vaccines and immunotherapeutics for the prevention and treatment of disease in areas that the Company believes to represent a significant opportunity for new vaccines | Directeur Technique/Scientifique/R&D | - |
Formation de Steven N. Chatfield
| University of Birmingham | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| EMERGENT BIOSOLUTIONS INC. | Health Technology |
| Entreprise privées | 9 |
|---|---|
Emergent Product Development UK Ltd.
Emergent Product Development UK Ltd. Pharmaceuticals: MajorHealth Technology Emergent Product Development (UK) Ltd. develops oral vaccines for typhoid, traveler's diarrhea, hepatitis B, and anthrax. It also develops vaccines for meningitis and another for streptococcal infections for infants. The company is a biotechnology company focused on harnessing the immune system to treat and prevent disease in areas of significant unmet clinical needs. It was founded in 1996 and is located in Wokingham, UK. | Health Technology |
Microscience Ltd.
Microscience Ltd. Pharmaceuticals: MajorHealth Technology Microscience is an emerging vaccine company which is primarily involved in the discovery and development of innovative, rationally designed vaccines and immunotherapeutics for the prevention and treatment of disease in areas that the Company believes to represent a significant opportunity for new vaccines | Health Technology |
Bio Defense Corp
Bio Defense Corp Chemicals: SpecialtyProcess Industries Part of Investco, Inc., Bio Defense Corp develops bio-chemical defense products used as disinfectants for mail ordered food products. The company is based in Burlington, MA. | Process Industries |
| Health Protection Agency | Government |
| Wellcome Foundation Ltd | Commercial Services |
Cell Therapy Catapult Ltd.
Cell Therapy Catapult Ltd. BiotechnologyHealth Technology Cell Therapy Catapult Ltd. engages in the development, delivery, and commercializing of cell and gene therapy. The company was founded in 2012 and is headquartered in London, the United Kingdom. | Health Technology |
Prokarium Ltd.
Prokarium Ltd. Miscellaneous Commercial ServicesCommercial Services Prokarium Ltd. operates as a biopharmaceutical company that focuses on developing vaccination solutions based on synthetic biology. Its oral vaccine delivery platform Vaxonella stimulates broad protective immune responses applicable to a wide range of diseases. The company is headquartered in Keele, the United Kingdom. | Commercial Services |
Vaccitech (UK) Ltd.
Vaccitech (UK) Ltd. Miscellaneous Commercial ServicesCommercial Services Vaccitech (UK) Ltd. researches in and develops seasonal flu vaccines. It engages in clinical programs for universal influenza and prostate cancer, MERS, and preclinical programs for other therapeutic infectious diseases indications. The company was founded by Adrian Hill and Sarah Gilbert and is headquartered in Oxford, the United Kingdom. | Commercial Services |
Prokarium Holdings Ltd.
Prokarium Holdings Ltd. Miscellaneous Commercial ServicesCommercial Services Prokarium Holdings Ltd. provides management services. The private company is based in London, UK. The British company was founded in 2014. Kristen Albright has been the CEO of the company since 2018. | Commercial Services |
